CINVENTION is a globally leading technology company providing disposable high performance processing and coating / drug delivery platform technologies. These proprietary technologies are known under the names from-lab-to-fab® and stent-of-the-art® technology.
From-lab-to-fab® technology:
From-lab-to-fab® technology is the key enabling technology for rapid product and process development and high yield bio-manufacturing that in parallel significantly reduces the time and costs by up to 70%. The basis is cultivation systems utilizing advanced nano-materials like CarboSeed® or CarboScale®.
From-lab-to-fab® technology allows high-efficient production of recombinant proteins and antibodies, vaccines, diagnostic compounds, and animal-compound-free cell based therapies, stem cell and primary cell cultivation. CINVENTION also provides CINTENSIFY® process development services based on from-lab-to-fab® technology for process intensification, automated bio-manufacturing and cost-effective multi-parallel manufacturing for vaccines, primary and adult stem cells, recombinant proteins.
Stent-of-the-art® technology:
CINVENTION has created a proprietary modular toolbox — the cintelligent® toolbox — for new classes of functional implant materials. Our library comprises more than 10,000 functional materials.
CINVENTION has invested more than 80 man years of technology development to define the next generation stent coatings for drug-eluting stents.
Starting from our first generation cequence® coating that utilizes the inherent properties of bio-inert inorganic carbon, CINVENTION can offer three generations of coating platforms today.
Additionally to a full-range of porous polymer-free coatings, we are proud to launch a bioactive, anti-thrombogenic gel-coating that expands scope from inorganic to a diversity of organic nano-composite coatings.
Besides defining new standard products we thrive to satisfy your needs by developing customized solutions. CINVENTION enables you to re-define the value chain and improve competitiveness in your markets.